Summary
UnitedHealth Group (UNH) reported a solid third quarter with revenues reaching $100.82 billion, a 9% increase year-over-year, driven by strong performance in both the UnitedHealthcare and Optum segments. UnitedHealthcare saw a 7% revenue increase, primarily due to growth in Medicare Advantage and domestic commercial offerings, although this was partially offset by Medicaid redeterminations and Medicare funding pressures. The Optum segment delivered a robust 13% revenue growth, spearheaded by Optum Rx and Optum Health, demonstrating the company's diversified growth strategy. While net earnings attributable to common shareholders saw a decrease of 48% to $8.86 billion for the nine months ended September 30, 2024, largely influenced by a significant $7.1 billion loss from the sale of Brazil operations and a $1.2 billion loss from classifying remaining South American operations as held for sale, the company's operational performance remains resilient. The company also continues to navigate the ongoing impacts of the Change Healthcare cyberattack, incurring response costs and business disruption impacts, though mitigation efforts are progressing. UNH remains committed to returning capital to shareholders through dividends and share repurchases, with an increased quarterly dividend declared.
Financial Highlights
55 data points| Revenue | $100.82B |
| Cost of Revenue | $11.83B |
| Gross Profit | $88.99B |
| SG&A Expenses | $13.28B |
| Operating Expenses | $92.11B |
| Operating Income | $8.71B |
| Interest Expense | $1.07B |
| Net Income | $6.05B |
| EPS (Basic) | $6.56 |
| EPS (Diluted) | $6.51 |
| Shares Outstanding (Basic) | 923.00M |
| Shares Outstanding (Diluted) | 930.00M |
Key Highlights
- 1Total revenues increased by 9% to $100.82 billion for the third quarter, driven by both UnitedHealthcare and Optum segments.
- 2UnitedHealthcare revenues grew 7% to $74.85 billion, supported by expansion in Medicare Advantage and domestic commercial business, serving 2.0 million more people domestically.
- 3Optum segment revenues surged by 13% to $63.93 billion, with Optum Rx and Optum Health showing strong double-digit growth.
- 4Net earnings attributable to common shareholders for the nine months ended September 30, 2024, were $8.86 billion, a decrease from $16.93 billion in the prior year, impacted by significant losses from the divestiture of Brazil operations ($7.1 billion) and South American operations held for sale ($1.2 billion).
- 5The company incurred $1.7 billion in direct response costs and business disruption impacts related to the Change Healthcare cyberattack for the nine months ended September 30, 2024.
- 6Cash flows from operations for the nine months ended September 30, 2024, were $21.8 billion, a decrease from $34.3 billion in the prior year, affected by cyberattack response actions and timing of CMS payments.
- 7The quarterly cash dividend was increased to an annual rate of $8.40 per share, reflecting confidence in ongoing financial performance and commitment to shareholder returns.